These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37499769)

  • 1. Activation of NLRP2 in Triple-Negative Breast Cancer sensitizes chemotherapeutic therapy through facilitating hnRNPK function.
    Jin L; Li T; Hong Y; Mao R; Li X; Zhu C; Mu J; Zhou J; Pan L; Que Y; Xia Y; Zhang Y; Li S
    Biochem Pharmacol; 2023 Sep; 215():115703. PubMed ID: 37499769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
    Yuan Z; Jiang H; Zhu X; Liu X; Li J
    Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NLRP2 inhibits cell proliferation and migration by regulating EMT in lung adenocarcinoma cells.
    Li T; Li X; Mao R; Pan L; Que Y; Zhu C; Jin L; Li S
    Cell Biol Int; 2022 Apr; 46(4):588-598. PubMed ID: 34957627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.
    Li T; Zhang Q; Zhang J; Yang G; Shao Z; Luo J; Fan M; Ni C; Wu Z; Hu X
    BMC Cancer; 2014 Feb; 14():96. PubMed ID: 24529079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLRP2 in health and disease.
    Zhang T; Xing F; Qu M; Yang Z; Liu Y; Yao Y; Xing N
    Immunology; 2024 Feb; 171(2):170-180. PubMed ID: 37735978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells.
    Jagadish N; Gupta N; Agarwal S; Parashar D; Sharma A; Fatima R; Topno AP; Kumar V; Suri A
    Tumour Biol; 2016 Oct; 37(10):13101-13110. PubMed ID: 27449044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of chrysin and radiotherapy against triple-negative breast cancer (TNBC) cell lines.
    Jafari S; Dabiri S; Mehdizadeh Aghdam E; Fathi E; Saeedi N; Montazersaheb S; Farahzadi R
    Clin Transl Oncol; 2023 Aug; 25(8):2559-2568. PubMed ID: 36964888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway.
    Xu X; Rajamanickam V; Shu S; Liu Z; Yan T; He J; Liu Z; Guo G; Liang G; Wang Y
    Drug Des Devel Ther; 2019; 13():3539-3550. PubMed ID: 31631978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
    Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
    Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of NLRP2 inhibits HUVEC viability by inhibiting the MAPK signaling pathway.
    Zhang X; Lu X; Yu L; Gu Y; Qu F
    Mol Med Rep; 2019 Jan; 19(1):85-92. PubMed ID: 30431084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
    Liao J; Qin QH; Lv FY; Huang Z; Lian B; Wei CY; Mo QG; Tan QX
    Sci Rep; 2023 Apr; 13(1):6211. PubMed ID: 37069240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
    Liang S; Peng X; Li X; Yang P; Xie L; Li Y; Du C; Zhang G
    Oncotarget; 2015 Jan; 6(2):1020-30. PubMed ID: 25544759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.